Clinical Trials Directory

Trials / Completed

CompletedNCT04424836

HFNC Treatment in COVID-19 Pneumonia

the Effect of HFNC Treatment on Mortality and Length of ICU Stay in Patient With COVID-19 Pneumonia

Status
Completed
Phase
Study type
Observational
Enrollment
43 (actual)
Sponsor
Sisli Hamidiye Etfal Training and Research Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

coronavirus disease 2019 related pneumonia is causing acute respiratory failure and this is the most common reason for ICU admission. We have several different way for respiratory support. HFNC is one of the new technics for oxygen support. Our main purpose to observe the effect of HFNC on coronavirus disease 2019 patients' ICU stay and mortality.

Detailed description

In the first group (group H), the data of patients undergoing HFNC treatment, and in group II (Group K), the data of patients who received COT with a reservoir mask were included. In HFNC support, the current air temperature is 31-37 degrees, the flow rate is 30-60 lt / min, and the FiO2 value is targeted so that saturation is 93% and above. Initially, continuous treatment was applied intermittently after the partial oxygen pressure / fraction of inspired oxygen(fio2) ratio exceeded 250 and clinical well-being occurred. In patients in Group K, fingertip saturation was targeted as 93% and above, and a COT was applied with a reservoir mask with a flow rate of 6-15 l / min. The flow rate was calculated using the formula of FiO2 (%) = 21 + 4 \* (liters / min) in patients undergoing COT. Noninvasive mechanical ventilation was applied to patients who could not be provided with adequate clinical and laboratory well-being in both groups (partial oxygen pressure / fraction of inspired oxygen ratio below 150) and invasive mechanical ventilation if this was insufficient.

Conditions

Interventions

TypeNameDescription
DEVICEhigh flow nasal cannula devicedevice is supplying oxygen with heated and humidified air in a high flow rate

Timeline

Start date
2020-05-15
Primary completion
2020-06-04
Completion
2020-06-05
First posted
2020-06-11
Last updated
2020-07-16

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT04424836. Inclusion in this directory is not an endorsement.